Co-Chief Scientific Officer · REGENERON PHARMACEUTICALS, INC. · Common Stock
Side
SELL
Value
$361K
Shares
463
Price
$780.63
Executed
Oct 14, 2026
Disclosed
Oct 15, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Oct 14 executedOct 15, 2026 disclosed
REGN · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Murphy Andrew J filed this Form 4 reporting a open-market sale of REGN on Oct 14, 2026. It became public on Oct 15, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Co-Chief Scientific Officer
Murphy Andrew Jcik:0001796226
Issuer
REGENERON PHARMACEUTICALS, INC.cik:0000872589
Revision history · 0
No field has changed since this record was first ingested.
